Capital Fund Management (CFM)
TVRD

Capital Fund Management (CFM)’s Tvardi Therapeutics TVRD Stock Holding History

Capital Fund Management (CFM)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-308
Closed -$171K – 1789
2017
Q2 		$171K Buy
+308
New +$195K ﹤0.01% 1394

Other funds holding TVRD

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Fund Management (CFM)'s TVRD Position: Q3 2017 in Review

Capital Fund Management (CFM) sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 308 shares — an estimated $171K sold.

Capital Fund Management (CFM) first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $171K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • Capital Fund Management (CFM) reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 308 Tvardi Therapeutics shares in Q3 2017, an estimated $171K.
  • Capital Fund Management (CFM) first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Tvardi Therapeutics position peaked at $171K in Q2 2017.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2017, filed 13 Nov 2017.